Caffeine therapy for apnea of prematurity.

@article{Schmidt2006CaffeineTF,
  title={Caffeine therapy for apnea of prematurity.},
  author={Barbara Schmidt and Robin S. Roberts and Peter Graham Davis and Lex William Doyle and Keith James Barrington and Arne Ohlsson and Alfonso J Solimano and Win Tin},
  journal={The New England journal of medicine},
  year={2006},
  volume={354 20},
  pages={
          2112-21
        }
}
BACKGROUND Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. [] Key Method We evaluated the short-term outcomes before the first discharge home.

Figures and Tables from this paper

Long-term effects of caffeine therapy for apnea of prematurity.
TLDR
Caffeine therapy for apnea of prematurity improves the rate of survival without neurodevelopmental disability at 18 to 21 months in infants with very low birth weight.
Duration of Caffeine for Apnea of Prematurity—A Randomized Controlled Trial
TLDR
Mandatorily continuing caffeine therapy up to 34 wk PMA in select preterm groups does not seem to decrease risk of recurrence of apnea, and larger trials that specifically study extremely preterm infants are required to make robust recommendations on when to stop therapy.
Caffeine Duration for Apnea of Prematurity: All Bets Are Off!
TLDR
The results of the current study do not inform clinical practice, but will form the basis for future trials to solve this clinical dilemma, as apnea can be a life-threatening event, especially in resourceconstraint settings.
Risks and benefits of methylxanthines therapy – Case study
TLDR
Lower postmenstrual age (less than 28,2 weeks) were associated with increased need for methylxanthines weight adjustments and mini-loads, as these infants required longer courses of therapy, and caffeine citrate was the preferred drug given its wider therapeutic margin, and fewer adverse effects.
Apnea of prematurity: caffeine dose optimization.
TLDR
In neonates less than 28 weeks gestational age, doses of caffeine citrate greater than 7.9 mg/kg/day are safe and are associated with a decreased need for clinical interventions.
Caffeine for Apnea of Prematurity: A Neonatal Success Story
TLDR
Caffeine for Apnea of Prematurity was an international, multicenter, placebo-controlled randomized trial designed to determine whether survival without neurodevelopmental disability at a corrected age of 18 months is improved if apnea of prematurity is managed without methylxanthines in infants at a high risk of apneic attacks.
Caffeine Treatment for Apnea of Prematurity and the Influence on Dose-Dependent Postnatal Weight Gain Observed Over 15 Years
TLDR
While a variety of measures are optimized to promote postnatal weight gain of premature infants close to an ideal intrauterine growth curve, not paying sufficient attention to one of the most widely used catabolic agents in neonatology is questionable and warrants vigilance.
Association of early versus late caffeine administration on neonatal outcomes in very preterm neonates
TLDR
In this third large-scale observational study of the Canadian Neonatal Network, Lodha et al. retrospectively investigated the effect of early versus late initiation of caffeine therapy on neonatal short-term outcomes of very preterm infants.
Apnoea of prematurity - discontinuation of methylxanthines in a resource-limited setting
TLDR
The main reason for discontinuing caffeine early was the baby’s ability to feed satisfactorily, a demonstration of physiological maturity, and as feeding behaviours mature significantly between 33 and 36 weeks, the ability toFeed may be a good indication that caffeine therapy can be stopped.
Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants
  • Dalal Taha, S. Kirkby, Z. Aghai
  • Medicine
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2014
TLDR
Early commencement of caffeine was associated with improvement in survival without BPD in preterm infants and an increase in the risk of nectrotizing enterocolits (NEC) with early caffeine use.
...
...

References

SHOWING 1-10 OF 32 REFERENCES
Methylxanthine Therapy for Apnea of Prematurity: Evaluation of Treatment Benefits and Risks at Age 5 Years in the International Caffeine for Apnea of Prematurity (CAP) Trial
TLDR
The main outcome at 5 years will be a composite of death or survival with severe disability in at least one of six domains: cognition, neuromotor function, vision, hearing, behavior, and general health.
Effect of Caffeine on Oxygen Consumption and Metabolic Rate in Very Low Birth Weight Infants With Idiopathic Apnea
TLDR
Long-term administration of caffeine in preterm infants is associated with an increase in oxygen consumption and with a reduction of weight gain, which may have implications for clinical practice as nutritional regimens need to be adjusted during this therapy.
The Natural History of the Appearance of Apnea of Prematurity
TLDR
Reduced respiratory drive, as demonstrated by airway occlusion pressures, was associated with more frequent apnea and was evident at the first occlusions study, which frequently preceded the first significant apnea.
Metabolic and respiratory effects of theophylline in the preterm infant
TLDR
After theophylline treatment, preterm infants had faster respiration, lower transcutaneous CO2, and improved static respiratory compliance without increased physical activity, which could be detrimental to the growth of the preterm infant.
Doxapram treatment for apnea in preterm infants.
TLDR
Although intravenous Doxapram might reduce apnea within the first 48 hours of treatment, there are insufficient data to evaluate the precision of this result or to assess potential adverse effects.
Oxygen consumption in apneic premature infants after low‐dose theophylline
TLDR
This dose of theophylline is effective in idiopathic apnea of prematurity and acts as a metabolic stimulant in the premature infant and increases in .
Doxapram treatment for apnea in preterm infants.
TLDR
Although intravenous doxapram might reduce apnea within the first 48 hours of treatment, there are insufficient data to evaluate the precision of this result or to assess potential adverse effects.
Effect of aminophylline on respiratory center activity and metabolic rate in premature infants with idiopathic apnea.
TLDR
Findings support the hypothesis that apnea in premature infants is related to an immature respiratory center characterized by a decreased output, and Aminophylline probably increases respiratory center output by lowering the threshold of the central chemorecepter to CO2.
Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks.
TLDR
Apnea of prematurity frequently persists beyond term gestation in infants delivered at 24 to 28 weeks' gestational age and these persistent apnea and/or bradycardia events may contribute to prolonged hospitalization.
Apnoea of prematurity.
...
...